N-(1-naphthyl)-N'-(m-tolyl)-N'-methylguanidine

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-(1-naphthyl)-N'-(m-tolyl)-N'-methylguanidine
• 英文别名: 1-methyl-1-(3-methylphenyl)-2-naphthalen-1-ylguanidine
• 化学式: C₁₉H₁₉N₃
• 分子量: 289.4
• InChiKey: LQXLWFNEBNMKQG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  methyl-m-tolyl-carbamonitrile 、 1-萘胺 、 盐酸 、 在 氮 、 silica gel 作用下， 反应 3.0h， 以to yield N-(1-naphthyl)-N'-(m-tolyl)-N'-methylguanidine的产率得到N-(1-naphthyl)-N'-(m-tolyl)-N'-methylguanidine
  参考文献：
  名称：

  Tri- and tetra-substituted guanidines and their use as excitatory amino

  摘要：

  三取代和四取代的胍基化合物，具有高结合亲和力与苯环哌啶（PCP）受体，更好的是，低亲和力与大脑sigma受体。这些胍基衍生物作为非竞争性抑制剂，通过作为NMDA受体离子通道复合物的通道阻滞剂，来阻止谷氨酸诱导的NMDA受体反应。这些化合物因此具有神经保护活性，并在治疗低氧、低血糖、脑或脊髓缺血和脑或脊髓创伤中的神经元丢失方面有用，同时也有用于治疗癫痫、阿尔茨海默病、肌萎缩性侧索硬化症、帕金森病、亨廷顿病、唐氏综合症、科萨科夫综合症和其他神经退行性疾病。

  公开号：

  US05798390A1

文献信息

• Tri-and tetra-substituted guanidines and their use as excitatory amino acid antagonists
  申请人：State of Oregon, acting by and through the Oregon State Board of Higher Education, acting for and on behalf of the Oregon Health Sciences University and the University of Oregon

  公开号：US06251948B1

  公开（公告）日：2001-06-26

  Tri- and tetra-substituted guanidines which exhibit a high binding affinity to phencyclidine (PCP) receptors and, more preferably, low affinity to the brain sigma receptors. These guanidine derivatives act as non-competitive inhibitors of glutamate induced responses of the NMDA receptor by acting as blockers for the ion channel of the NMDA receptor-ion channel complex. These compounds thus exert neuroprotective activity and are useful in the therapeutic treatment of neuronal loss in hypoxia, hypoglycemia, brain or spinal cord ischemia, and brain or spinal chord trauma as well as being useful for the treatment of epilepsy, Alzheimer's disease, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, Down's Syndrome, Korsakoff's disease and other neurodegenerative disorders.

  三取代和四取代的胍基化合物具有高结合亲和力，可以结合到苯环环庚啡（PCP）受体，更好的是，这些化合物对大脑σ受体的亲和力较低。这些胍基衍生物作为非竞争性抑制剂，通过作为NMDA受体离子通道复合物的通道阻滞剂，来抑制谷氨酸诱导的NMDA受体响应。因此，这些化合物具有神经保护作用，并可用于治疗缺氧、低血糖、脑或脊髓缺血、脑或脊髓创伤以及癫痫、阿尔茨海默病、肌萎缩性侧索硬化症、帕金森病、亨廷顿病、唐氏综合症、科萨科夫氏综合症和其他神经退行性疾病的治疗。
• Methods of treatment of eye trauma and disorders
  申请人：——

  公开号：US20030027801A1

  公开（公告）日：2003-02-06

  Methods are provided for treatment of eye disorders and injury, including methods for treatment of reduced flow of blood or other nutrients to retinal tissue and/or optic nerve, methods for treatment of retinal ischemia and trauma and methods for treatment for optic nerve injury/damage.

  提供了治疗眼部疾病和损伤的方法，包括治疗流向视网膜组织和/或视神经的血液或其他营养物质减少的方法、治疗视网膜缺血和创伤的方法以及治疗视神经损伤/损坏的方法。
• EP0517852A4
  申请人：——

  公开号：EP0517852A4

  公开（公告）日：1994-03-02
• TRI- AND TETRA-SUBSTITUTED GUANIDINES AND THEIR USE AS EXCITATORY AMINO ACID ANTAGONISTS
  申请人：STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of

  公开号：EP0517852A1

  公开（公告）日：1992-12-16
• METHODS OF TREATMENT OF EYE TRAUMA AND DISORDERS
  申请人：CAMBRIDGE NEUROSCIENCE, INC.

  公开号：EP0918460A1

  公开（公告）日：1999-06-02